All AbMole products are for research use only, cannot be used for human consumption.
Rimonabant is the first selective and orally active antagonist of the central brain cannabinoid receptor (CB1) with IC50 with 13.6 nM and EC50 with 17.3 nM in hCB1 transfected HEK 293 membrane .Rimonabant has been used to afford weight reduction and improvements in cardiometabolic risk factors, however is withdrawn in 2009 due to the severe depressive disorder and anxiety.Besides CB1 inhibition ability, Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2 . Moreover, Rimonabant significantly reduces cell growth and induces cell death of human colorectal cancer cells (DLD-1, CaCo-2 and SW620). Rimonabant is able to alter cell cycle distribution in all the cell lines tested. In the mouse model of azoxymethane-induced colon carcinogenesis, Rimonabant significantly decreased aberrant crypt foci (ACF) formation, which precedes colorectal cancer . Meanwhile, Rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats .
| Molecular Weight | 463.79 |
| Formula | C22H21Cl3N4O |
| CAS Number | 168273-06-1 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Ashish Samat, et al. Rimonabant for the treatment of obesity
[2] M Soyka. Rimonabant and depression
[3] A S Wierzbicki. Rimonabant: endocannabinoid inhibition for the metabolic syndrome
[4] C Curioni, et al. Rimonabant for overweight or obesity
[5] Steven Thomas Boyd, et al. Rimonabant--a selective CB1 antagonist
| Related Cannabinoid Products |
|---|
| UCM707
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide. |
| SCH 336
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. |
| JTE-907
JTE-907 is a highly selective, orally active CB2 receptor inverse agonist and exerts anti-inflammatory effects in vivo. |
| LEI-101
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. |
| AEF0117
AEF0117 is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
